Abbott India Confident Despite Phensedyl Problems
This article was originally published in PharmAsia News
Executive Summary
Abbott India, part of the US-based global healthcare company, says it is confident about the safety of its popular cough syrup Phensedyl, after it was reported that a government laboratory test found a sample bottle allegedly contained an excessive amount of codeine.
You may also be interested in...
Abbott's Top India Product Phensedyl Nosedives As India Faces Severe Codeine Shortage
MUMBAI - Drug maker Abbott may have leaped to the lead position in the Indian market with the much-hyped acquisition of Piramal Healthcare's formulations business, but data shows a three-fold sales decline of its lead brand, the cough syrup Phensedyl (chlorpheniramine/codeine), in the last eight months
Share Fillip As Indian Pharma Crests US Regulatory Hump
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Biocon, Quark Win Pioneering Indian Nod For RNAi Eye Therapy Trial
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.